In Vivo Real-time Detection of Circulating Melanoma Cells
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/3/2019 |
| Start Date: | February 2013 |
| End Date: | August 2020 |
| Contact: | Issam Makhoul, MD |
| Email: | MakhoulIssam@uams.edu |
| Phone: | 501-526-6990 |
The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry
(PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of
melanoma patients in vivo, in real time, and do so at detection limits at least one order of
magnitude below the detection limits of currently existing ex vivo methods.
(PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of
melanoma patients in vivo, in real time, and do so at detection limits at least one order of
magnitude below the detection limits of currently existing ex vivo methods.
Study Population: Approximately 80 subjects will be consented in order to achieve an
enrollment goal of 75 subjects at this institution in three cohorts as follows:
1. Cohort #1 will consist of fifteen healthy control subjects, ten of whom will be
Caucasian and five of whom will be African-American. Subjects in cohort #1 will be used
to address the calibration goal of Specific Aim #1.
2. Cohort #2 will consist of 30 subjects who have advanced-stage melanoma will be recruited
from the Medical Oncology clinic at UAMS, where advanced stages are defined as Stages
III or IV. Subjects in cohort #2 will be used to address the validation goal of Specific
Aim #2. Approximately half of the 30 advanced-stage subjects will be Stage III and the
other half will be Stage IV.
3. Cohort #3 will consist of 30 subjects with early-stage melanoma will be recruited from
the Surgical Oncology clinic at UAMS, where early stages are defined as Stages I or II.
Subjects in cohort #3 will be used to address the detection goal of Specific Aim #3.
Approximately 10 of the 30 early-stage subjects will be Stage I and approximately 20 will be
Stage II.
enrollment goal of 75 subjects at this institution in three cohorts as follows:
1. Cohort #1 will consist of fifteen healthy control subjects, ten of whom will be
Caucasian and five of whom will be African-American. Subjects in cohort #1 will be used
to address the calibration goal of Specific Aim #1.
2. Cohort #2 will consist of 30 subjects who have advanced-stage melanoma will be recruited
from the Medical Oncology clinic at UAMS, where advanced stages are defined as Stages
III or IV. Subjects in cohort #2 will be used to address the validation goal of Specific
Aim #2. Approximately half of the 30 advanced-stage subjects will be Stage III and the
other half will be Stage IV.
3. Cohort #3 will consist of 30 subjects with early-stage melanoma will be recruited from
the Surgical Oncology clinic at UAMS, where early stages are defined as Stages I or II.
Subjects in cohort #3 will be used to address the detection goal of Specific Aim #3.
Approximately 10 of the 30 early-stage subjects will be Stage I and approximately 20 will be
Stage II.
Inclusion Criteria:
- Age 18 to 80 years
- Histological documented diagnosis of melanoma
- Signed informed consent form approved by the University of Arkansas for Medical
Sciences (UAMS) Institutional Review Board (IRB)
- Must be able to sit still for 90 minutes
Exclusion Criteria:
- Active infection
- Current and significant medical or surgical condition as determined by the
Investigator
- Diagnosis or evidence of organic brain syndrome
- Pregnancy or breastfeeding
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Fade Mahmoud
Phone: 501-603-1213
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
